Drugs / (64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04167969 | Feb 2021 → Nov 2027 expected | prostate cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04167969 ↗ |
| Known as | 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots | “The purpose of this study is to see whether using the copper-64 (64Cu) or zirconium-89 (89Zr) radiolabeled PSMA-targeting C' dot tracer, termed 64Cu-NOTA-PSMAi-PEG-Cy5.5-C'...” NCT04167969 ↗ |
| Modality | Diagnostic / imaging agent | “copper-64 (64Cu) or zirconium-89 (89Zr) radiolabeled PSMA-targeting C' dot tracer” NCT04167969 ↗ |
| Route | Intravenous | “Patients will receive an intravenous (IV) injection of approximately 6-7 mCi (+/- 10%) of PSMA-targeting C' dot tracer up to 48 h before surgery” NCT04167969 ↗ |